FDA simplifies Covid-19 bivalent vaccination process ahead of June adcomm
The FDA is modifying the emergency use authorization for Moderna and Pfizer/BioNTech’s Covid-19 vaccines by removing the two-dose primary series (except for children) and the original monovalent vaccines, and allowing for those over 65 to receive one additional bivalent dose at least four months after a first one.
Federal regulators put out word Tuesday that the bivalent vaccines, which can protect against both the original SARS-CoV-2 strain and against Omicron BA.4/BA.5, can now be used for all vaccine doses given to those at least 6 months old.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.